Customising therapy in femoropopliteal revascularisation

Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based therapies have become a mainstay in femoropopliteal revascularisation and how interventionalists should be using best medical therapy “more than we do [currently]”. He also shares his approach to making the choice between using a drug-coated balloon and a drug-eluting stent.

Ansel, Gary

During his 30-year career, Ansel has published numerous articles on femoral artery disease, critical limb ischemia and, most recently, drug-coated balloons, as well as other topics in vascular intervention. He has been a primary investigator on numerous cutting-edge trials and has presented on behalf of many technologies to the FDA and the CMS. Ansel is also a founding board member of VIVA Physicians.

Add comment

Editor’s Peripheral Pick

    Subscribe to receive the very best in medical videos

    /* ]]> */